Abstract
We conducted a Phase II study of PROMACE-MOPP and intrathecal (IT) therapy followed by cranial radiation in 7 patients (4 male, 3 females) with diffuse large cell lymphomas (including one T cell) involving the central nervous system (CNS). Median age was 47 years (range, 25–78). Median performance status was 2 (range, 2 to 3). Two patients had positive CSF cytology. No patients had prior chemotherapy or radiotherapy. Treatment consisted of PROMACE (cyclophosphamide 650 mg/m2, Adriamycin 25 mg/m2, etoposide 120 mg/m2 days 1 and 8, methotrexate (MTX) 1.5 g/m2 and folinic acid 50 mg/m2 (× 5) day 15, and prednisone 60 mg/m2 days 1–14) × 3–4 courses. MOPP consisted of mustargen 6 mg/m2 and vincristine 1.4 mg/m2 days 1 and 8, procarbazine 100 mg/m2 and prednisone 40 mg/m2 po days 1–14 × 3–4 courses. IT drugs were MTX 20 mg and hydrocortisone 20 mg day 1 and cytosine arabinoside 100 mg day 8, courses 2 to 6, or more frequently if CSF cytology was positive. Following MOPP, 4000 cGy whole brain radiation (XRT) and 2000 cGy boost was given. Response was evaluated before XRT Two patients declined XRT, 3 declined MOPP and 2 declined IT drugs. Two patients had extracerebral disease and 5 were primary CNS lymphomas. Response after PROMACE was CR: 3 patients; PR 2: stable 1. One patient, with extracerebral disease, experienced PR in the abdomen and CR by CT scan in the brain, but had persistent positive CSF cytology. This patient died from pneumocystis pneumonia 10 weeks after her last CSF cytology and 17 weeks after her diagnosis. After PROMACE +/- MOPP 6 patients experienced CR's. Median (range) survival was 100 (17–334) weeks, with 1 patient lost to follow up at 32 weeks. Toxicity included febrile neutropenia; 6 patients; pneumocystis pneumonia: 1 (fatal); thrombocytopenia; 5; stomatitis: 3; diarrhea; 2; nausea; 3. Conclusion: This regimen is active in the treatment of CNS lymphomas, although toxicity is substantial.
Similar content being viewed by others
References
Bierman PJ, Vose JM, Armitage JO: Clinical manifestations, staging and treatment of non-Hodgkin's lymphoma. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ (eds) Hematology Basic Principles and Practice, Churchill Livingstone Publishers, New York 963–982, 1991
DeAngelis LM, Yahalom J, Rosenblum M, Posner JB: Primary CNS lymphoma: managing patients with spontaneous and AIDS-related disease. Oncology 1(6): 52–62, 1987
Hoerni-Simon G, Suchaud JP, Eghbali H, Hoerni B: Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma: A study of 30 cases in a series of 498 patients. Oncology 44: 98–101, 1987
DeAngelis LM, Yahalom J, Heinemann MH, Cirrincione C, Thaler HT, Krol G: Primary CNS lymphoma: Combined treatment with chemotherapy and radiotherapy. Neurology 40: 80–86, 1990
Leibel SA, Sheline GE: Radiation therapy for neoplasms of the brain. J Neurosurg 66: 1–22, 1987
Woodman R, Shin K, Pineo G: Primary non-Hodgkins lymphoma of the brain: A review. Medicine 64(6): 423–430, 1985
Neuwelt EA, Balaban E, Diehl J, Hill S, Frenkel E: Successful treatment of primary central nervous system lymphoma with chemotherapy after osmotic blood-brain barrier opening. Neurosurgery 12(6): 662–671, 1983
Stewart DJ: A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neuro-Oncol 20: 121–139, 1994
Ervin T, Canellos GP: Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer 45: 1556–1557, 1980
Herst KD, Corder MP, Justice GR: Successful therapy with methotrexate of a multicentric mixed lymphoma of the central nervous system. Cancer 38: 1476–1478, 1976
Stewart DJ, Russell N, Atack EA, Quarrington A, Stolbach L: Cyclophosphamide, doxorubucin, vincristine and dexamethasone in primary lymphoma of the brain: A case report. Cancer Treat Rep 67(3): 287–291, 1983
Kawakami Y, Tabuchi K, Rinkichi O, Asari S, Nishimoto A: Primary central nervous system lymphoma. J Neurosurg 62: 522–527, 1985
Shibamoto Y, Tsutsui K, Dodo Y, Yamabe H, Shima N, Abe M: Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine doxorubicin-cyclophosphamide-prednisolone chemotherapy. Cancer 1907–1912, 1990
Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, Braziel R, Dana B: Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol 9(9): 1580–1590, 1991
Fisher RI, DeVita VT, Hubbard SM, Longo DL, Wesley R, Chabner BA, Young RC: Diffuse aggressive lymphoma: Increased survival after alternating flexible sequences of ProMace and MOPP chemotherapy. Ann Int Med 98: 304–309, 1983
Fisher RI, Gaynor ER, Dahlburg S, Oken MM, Grogan TM, Mize EM, Glick JH, Colatman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkins lymphoma. New Eng J Med 328(14): 1002–1006, 1993
Jellinger K, Radaskiewicz TH, Slowik F: Primary malignant lymphoma of the central nervous system in man. Acta Neuropathol (Berlin) 95: 102, 1975
Hochberg FH, Miller DC: Primary central nervous system lymphoma. J Neurosurg 68: 835–853, 1988
Murray K, Kun L, Cox J: Primary malignant lymphoma of the central nervous system. J Neurosurg 65: 600–607, 1986
Jiddane M, Nicol F, Diaz P, Bergvall U, Vincentelli F, Hassoun J, Salamon G: Intracranial malignant lymphoma. Report of 30 cases and review of the literature. J Neurosurg 65: 592–599, 1986
Letendre L, Banks PM, Reese DF, Miller RH, Scanlon PW, Kiely JM: Primary lymphoma of the central nervous system. Cancer 49: 939–943, 1982
Littman P, Wang CC: Reticulum cell sarcoma of the brain. A review of the literature and a study of 19 cases. Cancer 35: 1412–1420, 1975
Helle TL, Britt RH, Colby TV: Primary lymphoma of the central nervous system. Clinicopathological study of experience at Stanford. J Neurosurg 60: 94–103, 1984
Stewart DJ, Smith TL, Keating MJ, Maor M, Leavens M, Hurtubise M, McCredie KB, Bodey GP Sr, Freireich EJ: Remission from central nervous system involvement in adults with acute leukemia. Effect of intensive therapy and prognostic factors. Cancer 56(3): 632–641, 1885
Sullivan MP, Moon TE, Trueworthy R, Vietti TJ, Humphrey GB, Komp D: Combination intrathecal therapy for meningeal leukemia: Two versus three drugs. Blood 51: 471–479, 1977
Stewart DJ, Russell JD, Richard MT, Atack E, Eapen L, Girard A, Maroun JA, Grahovac Z, Belanger G: Cyclophosphamide, adriamycin, vincristine and dexamethasone in the treatment of bulky central nervous system lymphoma. In: Walker MD, Thomas DGT (eds) Biology of Brain Tumour, Martinus Nijhoff Publishers, Boston 433–435, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dent, S., Eapen, L., Girard, A. et al. PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas. J Neuro-Oncol 28, 25–30 (1996). https://doi.org/10.1007/BF00300443
Issue Date:
DOI: https://doi.org/10.1007/BF00300443